Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Naproxen metabolism in man.

Journal of Clinical Pharmacology

|April 1, 1975

Summary

This summary is machine-generated.

Naproxen is readily absorbed and has a 13-hour half-life, suitable for twice-daily dosing. While drug interactions are possible due to albumin binding, they are not clinically significant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

'Treatment IND' is an oxymoron.

JAMA·1988

Same author

Naproxen sodium (Anaprox): pharmacology, pharmacokinetics and drug interactions.

The Journal of reproductive medicine·1980

Same author

Correlation of flunisolide plasma levels to eosinopenic response in humans.

The Journal of allergy and clinical immunology·1980

Same author

The treatment of dysmenorrhea with naproxen sodium. A report on two independent double-blind trials.

Obstetrical & gynecological survey·1977

Same author

The treatment of dysmenorrhea with naproxen sodium: a report on two independent double-blind trials.

American journal of obstetrics and gynecology·1977

Same author

Combination therapy with naproxen and aspirin in rheumatoid arthritis.

Arthritis and rheumatism·1976

Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026

Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026

Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026

Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026

Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026

Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026

See all related articles

Area of Science:

Pharmacology
Drug Metabolism
Clinical Pharmacokinetics

Background:

Naproxen is an acidic, nonsteroidal anti-inflammatory drug (NSAID) widely used for pain and inflammation.
Understanding its pharmacokinetic profile is crucial for optimizing therapeutic use and managing potential drug interactions.

Purpose of the Study:

To summarize the pharmacokinetic properties of naproxen in humans.
To evaluate the impact of albumin binding on naproxen's plasma levels and potential drug interactions.

Main Methods:

Review of existing pharmacokinetic data for naproxen.
Analysis of absorption, distribution, metabolism, and excretion (ADME) parameters.
Assessment of naproxen's binding kinetics to serum albumin and its implications.

Related Experiment Videos

Main Results:

Naproxen is rapidly and completely absorbed orally, with a mean half-life of 13 hours, supporting twice-daily dosing.
The primary metabolite is 6-desmethyl naproxen, with both parent drug and metabolite excreted renally as conjugates.
High albumin binding limits plasma levels; doses above 500 mg twice daily show minimal increase in concentration due to rapid clearance.

Conclusions:

Naproxen's pharmacokinetic profile is favorable for twice-daily administration.
Albumin binding influences naproxen's pharmacokinetics and can lead to potential interactions, though currently not considered clinically significant.